Industry News Archives | International Rett Syndrome Foundation

June 19, 2025

Taysha Gene Therapies Updates on Part A Data, Plans for the Part B Pivotal Study, and FAQs (Community Letter)

Filter

Anavex

Long-term Clinical Study Demonstrates Disease-Modifying Effects of ANAVEX®2-73 for Rett Syndrome

Taysha

Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day

Neurogene

Neurogene Opens Enrollment for U.S. Gene Therapy Clinical Trial (Community Letter)

Anavex

Completion of ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

Taysha

Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome

Acadia

Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome

Neurotech

Neurotech to Launch Phase II Clinical Trial in Rett Syndrome

Acadia

Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older

Acadia

LILAC-1 Study Topline Results Announced (Community Letter)